# Deployments

This page tracks all Glorbit deployments across global partner sites. Not every site listed here will turn into a partner site, but these are the identified targets based on local connections and diversity of patient populations. Ideal sites are in low resource areas. Ideally, 3-5 sites total will be enrolled in the study. 

---

## Deployment Summary

| **Site**                 | **Country**  | **Tier**                                        | **Status**                                      | **IRB Status**                 | **Expected Enrollment** | **Collaborators**                              |
|--------------------------|--------------|--------------------------------------------------|--------------------------------------------------|--------------------------------|--------------------------|-----------------------------------------------|
| *Quina Care*             | Ecuador      | <span class="tier-badge tier1">Tier 1</span>     | Live deployment; >100 patients enrolled          | Approved (USFQ 2025-037E)      | 200                      | Quina Care, USFQ, UIC                         |
| *Shell Hospital*         | Ecuador      | <span class="tier-badge tier1">Tier 1</span>     | Early-stage coordination                         | Amendment to 2025-037E in progress | 500                   | Shell Hospital, USFQ, UIC                     |
| *Honduras*               | Honduras     | <span class="tier-badge tier2">Tier 2</span>     | In early discussion                              | IRB template drafted in Spanish | 500                      | Dr. Setabutr, Dr. Chan, Dr. MacIntosh         |
| *Puno*                   | Peru         | <span class="tier-badge tier2">Tier 2</span>     | Contact made; early planning                     | IRB template drafted in Spanish | 500                      | Puno Regional Hospital, GW collaborators      |
| *Thailand*               | Thailand     | <span class="tier-badge tier2">Tier 2</span>     | High interest                                    | Not yet drafted                | 500                      | Dr. Setabutr, Dr. Chan                        |
| *India*                  | India        | <span class="tier-badge tier2">Tier 2</span>     | High interest                                    | Not yet drafted                | 500                      | Dr. Setabutr, Dr. Chan                        |
| *Labuan Bajo (Flores)*   | Indonesia    | <span class="tier-badge tier3">Tier 3</span>     | Outreach initiated                               | KEPK IRB required              | 500                      | Larrick network                              |
| *Sierra Leone*           | Sierra Leone | <span class="tier-badge tier3">Tier 3</span>     | Initial conversations                            | Not yet drafted                | 500                      | Dr. Yeh, Dr. Setabutr, Dr. Chan               |
| *Bhutan*                 | Bhutan       | <span class="tier-badge tier3">Tier 3</span>     | Outreach initiated                               | Not yet drafted                | 500                      | Larrick network                              |
| *Mongolia*               | Mongolia     | <span class="tier-badge tier3">Tier 3</span>     | High interest                                    | Not yet drafted                | 500                      | Dr. Chan                                     |

### Interpretation of Tiers

| **Tier**                                       | **Meaning**                                                                                                          |
| ---------------------------------------------- | -------------------------------------------------------------------------------------------------------------------- |
| *Tier 1 — Active / Near-Term Deployments*    | Sites already live or where deployment is imminent. These will contribute the first wave of global prospective data. |
| *Tier 2 — High-Probability 2026 Deployments* | Strong institutional partnerships and clear next steps; high likelihood to activate within the fellowship timeline.           |
| *Tier 3 — Exploratory Sites*                 | Long shots, but some on the ground relations present      |

---

## Individual Site Progress

This section contains progress tracking for each active or prospective site. Expand the box to see the progress and next steps.

??? deploy-tier1 "Quina Care, Ecuador — Tier 1"

    Primary deployment site for Glorbit 1. Located in Putumayo in the Ecuadorian Amazon.

    **IRB:** USFQ 2025-037E  
    **Partners:** Quina Care, USFQ, UIC  
    **Goals:** 200 enrolled patients  

    <div data-progress>
    <ul>
      <li class="done">Contact made</li>
      <li class="done">Hospital intent letter acquired</li>
      <li class="done">IRB approved</li>
      <li class="done">Deployment of Glorbit</li>
      <li class="done">Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier1 "Shell Hospital, Ecuador — Tier 1"
    Second Ecuadorian deployment. Complementary patient population.

    **IRB:** Amendment to USFQ 2025-037E  
    **Partners:** Shell Hospital, USFQ, UIC  

    <div data-progress>
    <ul>
      <li class="done">Contact made with local champion and verbal agreement</li>
      <li>Hospital intent letter acquired</li>
      <li>Modification of existing IRB submitted</li>
      <li>IRB amendment approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier2 "Honduras — Tier 2"
    Sites in Honduras to be identified in collaboration with Dr. Setabutr, Dr. Chan, Sasha, and Dr. MacIntosh.

    **IRB:** To be initiated  
    **Partners:** TBD  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier2 "Thailand — Tier 2"
    Sites in Thailand to be identified in collaboration with Dr. Setabutr.

    **IRB:** To be initiated  
    **Partners:** TBD  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier2 "India — Tier 2"
    Sites in India to be identified in collaboration with Dr. Setabutr and Dr. Chan.

    **IRB:** To be initiated  
    **Partners:** TBD  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier2 "Puno, Peru — Tier 2"
    Sites in Peru to be identified in collaboration with GW collaborators.

    **IRB:** To be initiated  
    **Partners:** Puno regional hospital  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier3 "Mongolia — Tier 3"
    Sites in Mongolia to be identified in collaboration with Dr. Setabutr and Dr. Chan.

    **IRB:** To be initiated  
    **Partners:** TBD  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier3 "Indonesia — Tier 3"
    Sites in Indonesia to be identified in collaboration with Dr. Larrick.

    **IRB:** Indonesian KEPK (to be initiated)  
    **Partners:** Local surgical outreach team  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---

??? deploy-tier3 "Sierra Leone — Tier 3"
    Sites in Sierra Leone to be identified in collaboration with Dr. Setabutr, Dr. Yeh, and Dr. Chan.

    **IRB:** To be initiated  
    **Partners:** TBD  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>

---


??? deploy-tier3 "Bhutan — Tier 3"
    Sites in Bhutan to be identified in collaboration with Dr. Larrick.

    **IRB:** To be initiated  
    **Partners:** Local surgical outreach team  

    <div data-progress>
    <ul>
      <li>Contact made with local champion</li>
      <li>Hospital intent letter acquired</li>
      <li>IRB drafted</li>
      <li>IRB approved</li>
      <li>Deployment of Glorbit</li>
      <li>Enrollment of 100 patients</li>
      <li>Enrollment of 200 patients</li>
      <li>DUA with UIC and IRB STUDY2024-1118</li>
      <li>Data analysis</li>
    </ul>
    </div>


---

## Deployment Workflow

The protocol to enroll new sites is roughly the same at each new enrollment, with the primary difference being local regulations regarding ethical approval.

1. Identify local clinical champion  
2. Obtain hospital intent letter  
3. Prepare and submit local IRB  
4. Secure IRB approval  
5. Deploy Glorbit and train operators  
6. Collect 100–500 patient images + metadata  
7. Establish Data Use Agreement (DUA) with UIC  
8. Transfer data and initiate analysis  

<!-- 
---

## **Quina Care, Ecuador**

Primary deployment site for Glorbit 1. Located in Putumayo in the Ecuadorian Amazon.

**IRB:** USFQ 2025-037E  
**Partners:** Quina Care, USFQ, UIC  
**Goals:** 200 enrolled patients, validated workflow, prospective dataset assembly  

<div data-progress>
<ul>
  <li class="done">Contact made with local champion and verbal agreement</li>
  <li class="done">Hospital intent letter acquired</li>
  <li class="done">IRB approved from USFQ (2025-037E)</li>
  <li class="done">Deployment of Glorbit</li>
  <li class="done">Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Shell Hospital, Ecuador**

Second Ecuadorian deployment. Urban setting, complementary patient population.

**IRB:** Amendment to USFQ 2025-037E  
**Partners:** Shell Hospital, USFQ, UIC  

<div data-progress>
<ul>
  <li class="done">Contact made with local champion and verbal agreement</li>
  <li>Hospital intent letter acquired</li>
  <li>Modification of existing IRB submitted</li>
  <li>IRB amendment approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Honduras**

Sites in Honduras to be identified in collaboration with Dr. Setabutr, Dr. Chan, Sasha, and Dr. MacIntosh.

**IRB:** To be initiated  
**Partners:** TBD  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Thailand**

Sites in Thailand to be identified in collaboration with Dr. Setabutr.

**IRB:** To be initiated  
**Partners:** TBD  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **India**

Sites in India to be identified in collaboration with Dr. Setabutr and Dr. Chan.

**IRB:** To be initiated  
**Partners:** TBD  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Mongolia**

Sites in Mongolia to be identified in collaboration with Dr. Setabutr and Dr. Chan.

**IRB:** To be initiated  
**Partners:** TBD  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Indonesia**

Sites in Indonesia to be identified in collaboration with Dr. Larrick.

**IRB:** Indonesian KEPK (to be initiated)  
**Partners:** Local surgical outreach team  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Africa**

Sites in Sierra Leone to be identified in collaboration with Dr. Setabutr, Dr. Yeh, and Dr. Chan.

**IRB:** To be initiated  
**Partners:** TBD  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Puno, Peru**

Sites in Peru to be identified in collaboration with GW collaborators.

**IRB:** To be initiated  
**Partners:** Puno regional hospital  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div>

---

## **Bhutan**

Sites in Bhutan to be identified in collaboration with Dr. Larrick.

**IRB:** To be initiated  
**Partners:** Local surgical outreach team  

<div data-progress>
<ul>
  <li>Contact made with local champion</li>
  <li>Hospital intent letter acquired</li>
  <li>IRB drafted</li>
  <li>IRB approved</li>
  <li>Deployment of Glorbit</li>
  <li>Enrollment of 100 patients</li>
  <li>Enrollment of 200 patients</li>
  <li>DUA with UIC and IRB STUDY2024-1118</li>
  <li>Data analysis</li>
</ul>
</div> -->